1. Scrip
  2. >>Business

Gene Editing Excels As Regenerative Medicine Reaches Record Investments

Says Alliance for Regenerative Medicine

 
• By Ayisha Sharma

Gene and cell-based therapeutics attracted the bulk of regenerative medicine investment last year, with gene-editing approaches garnering confidence following key clinical milestones, new research shows.  

Business man hitting brick grungy wall with hammer and opening a hole
Gene Editing Therapies Are Helping Break Investment Records • Source: Alamy

As confidence in gene-editing therapy grows, investment in regenerative medicines has more than tripled since 2017, according to a new report by the Alliance for Regenerative Medicine.

Regenerative medicine firms raised an impressive $22.7bn last year, breaking the previous record of $19.9bn in 2020 by 14%, according to the alliance’s annual report, Regenerative Medicine: Disrupting the Status Quo. Venture capital was the main driver of this increase, accounting for $9.8bn of the total while 26 IPOs contributed $4.8bn

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.